Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Harvard BioscienceFRA:HBI0 53 Quick Ratio is 0.98 as of Jun. 2026, which is 17% below its 10-year median of 1.18. GuruFocus rates FRA:HBI0 with a GF Score™ of 53/100 and a GF Value™ of €6.70. The stock has 9 warning signs investors should review. Among 850 Medical Devices & Instruments companies, Harvard Bioscience ranks worse than 78.12% on this metric.
Harvard Bioscience has a quick ratio of 0.98. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Harvard Bioscience's Quick Ratio or its related term are showing as below:
FRA:HBI0'
s Quick Ratio Range Over the Past 10 Years
Min: 0.4 Med: 1.18 Max: 2.19
Current: 0.98
During the past 13 years, Harvard Bioscience's highest Quick Ratio was 2.19. The lowest was 0.40. And the median was 1.18.
FRA:HBI0's Quick Ratio is ranked worse than 78.12% of 850
companies
in the Medical Devices & Instruments industry
Industry Median: 1.89
vs FRA:HBI0: 0.98
Harvard Bioscience (FRA:HBI0) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Harvard Bioscience Quick Ratio Related Terms
Harvard Bioscience Quick Ratio Historical Data
* Premium members only.
The historical data trend for Harvard Bioscience's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:HBI0 vs RVP, MLSS, ZJYL: Quick Ratio Comparison
For the Medical Instruments & Supplies subindustry, Harvard Bioscience's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harvard Bioscience Quick Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Harvard Bioscience's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Harvard Bioscience's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harvard Bioscience (FRA:HBI0) has a Quick Ratio of 0.98 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Harvard Bioscience and its competitors. This is 17% below median its historical median of 1.18. Over the past decade, Harvard Bioscience's Quick Ratio has ranged from 0.40 to 2.19. According to the industry distribution chart, Harvard Bioscience ranks #664 out of 850 companies in the Medical Devices & Instruments industry, placing it in the top 78.1%.
Is Harvard Bioscience's Quick Ratio too high?
Harvard Bioscience's current Quick Ratio of 0.98 is 17% below median its 10-year median of 1.18. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 2.19. The Medical Devices & Instruments industry median Quick Ratio is 1.89. Harvard Bioscience's value of 0.98 is 48.1% below this industry median. Based on the distribution chart, Harvard Bioscience ranks #664 out of 850 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Harvard Bioscience has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's Quick Ratio compare to RVP and MLSS?
According to the Medical Devices & Instruments industry distribution chart, Harvard Bioscience ranks #664 out of 850 companies for Quick Ratio. This places Harvard Bioscience in the lower half of its industry. The industry median Quick Ratio is 1.89. Harvard Bioscience's value of 0.98 is 48.1% below this benchmark. Historically, Harvard Bioscience's own Quick Ratio has ranged from 0.40 to 2.19 over the past decade. While the company's 10-year median is 1.18 vs. the industry median of 1.89, Harvard Bioscience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Devices & Instruments company?
The median Quick Ratio among Medical Devices & Instruments companies is 1.89, based on 850 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harvard Bioscience's current Quick Ratio of 0.98 is 48.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Harvard Bioscience and its competitors. For the Medical Devices & Instruments industry, the median Quick Ratio is 1.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harvard Bioscience's current Quick Ratio is 0.98, which is 17% below median its own 10-year median of 1.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Harvard Bioscience (FRA:HBI0) has a current Quick Ratio of 0.98. The stock's GF Value™ is €6.70, compared to a current price of €4.08 — trading 39.1% below its estimated fair value. The current Quick Ratio is 0.98, which is 17% below median its 10-year median of 1.18 and 48.1% below the Medical Devices & Instruments industry median of 1.89. Harvard Bioscience's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Harvard Bioscience (FRA:HBI0), the current Quick Ratio is 0.98 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harvard Bioscience (FRA:HBI0) Overvalued in 2026?
Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued.
The current stock price of €4.08 is trading 39.1% below its estimated GF Value™ of €6.70.
Key valuation signals for FRA:HBI0:
Quick Ratio: 0.98 (17% below median its 10-year median of 1.18)
GF Value™: €6.70 vs. price of €4.08 (39.1% below fair value)
Industry Position: 48.1% below the Medical Devices & Instruments median (#664 of 850)
No single metric tells the full story. See the FRA:HBI0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
53GF Score
Get the complete analysis for FRA:HBI0
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HBI0 has been successfully added to your 
